Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21719450 | 0.79 | DYRK1A (0.33) | DYRK1A | |
| SCHEMBL12121211 | 0.76 | DYRK1A (0.46) | DYRK1AL3MBTL1 | |
| SCHEMBL3465033 | 0.74 | DYRK1A (0.33) | DYRK1AL3MBTL1 | |
| SCHEMBL3402634 | 0.73 | DYRK1A (0.32) | DYRK1AL3MBTL1 | |
| SCHEMBL3464724 | 0.73 | L3MBTL1 (0.39) | DYRK1AL3MBTL1 | |
| SCHEMBL2875793 | 0.73 | ALOX15 (0.34) | DYRK1AL3MBTL1 | |
| SCHEMBL13748111 | 0.71 | DYRK1A (0.31) | DYRK1AL3MBTL1 | |
| SCHEMBL13755079 | 0.70 | P2RX7 (0.33) | DYRK1AL3MBTL1 | |
| SCHEMBL19661158 | 0.70 | DYRK1A (0.30) | DYRK1AL3MBTL1 | |
| SCHEMBL3263071 | 0.69 | LRRK2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941132-B2 | Pyrazole derivatives | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2021-03-09 | — | — | US | disclosed |
| US-20190002432-A1 | PYRAZOLE DERIVATIVES | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2019-01-03 | — | — | US | disclosed |
| WO-2017117708-A1 | PYRAZOLE DERIVATIVES | HUA MEDICINE (SHANGHAI) LTD. (CN) | 2017-07-13 | — | — | WO | disclosed |
| US-8324216-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| CN-100542534-C | Substituted piperazines | CHEMOCENTRYX INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| CN-1913898-A | Substituted piperazines | CHEMOCENTRYX INC (US) | 2007-02-14 | — | — | CN | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941132-B2 | Pyrazole derivatives | GRM5, GRIK5, GRIN2C | DYRK1A 3502/4885L3MBTL1 3222/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | DYRK1A 4508/4885L3MBTL1 1589/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | DYRK1A 4508/4885L3MBTL1 1589/4885 |
| US-20190002432-A1 | PYRAZOLE DERIVATIVES | GRM5, GRIK5, GRIN2C | DYRK1A 3502/4885L3MBTL1 3222/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | DYRK1A 4508/4885L3MBTL1 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.